Latest close: below its 200-day averageSep 8, 2026what changed →
The financials
Penumbra, Inc. by the numbers
Penumbra, Inc. (PEN) reported revenue of $375M in Q1 2026 (quarter ended Mar 31, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $33M (8.7% of revenue). For the full year FY2025, revenue was $1.40B (+17% year on year) and net income $178M. Its largest product in Jun 2026 was Thrombectomy at $259M, 66% of the disclosed total, well ahead of Embolization And Access at 34%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $375M | $324M | +16% |
| Gross profit | $253M | $216M | +17% |
| Operating income | $38M | $40M | −5.2% |
| Net income | $33M | $39M | −17% |
| Diluted EPS | $0.82 | $1.00 | −18% |
| Product | Revenue | Share |
|---|---|---|
| Thrombectomy | $259M | 66% |
| Embolization And Access | $131M | 34% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $390.0M (+4.1%)
Embolization And Access grew +20% year on yearThrombectomy +12% year on year
Segment Latestquarter on quarteryear on year
- Thrombectomy$259.0M$259.0MQoQ +2.0%year on year +12%+2.0%+12%
- Embolization And Access$131.1M$131.1MQoQ +8.5%year on year +20%+8.5%+20%
Medical Devices
Ranks #12 of 29 by Smart Score